Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.64 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.64 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.64 |
| ▸ | LMNA | P02545 | 3/20 | 0.64 |
| ▸ | CXCR1 | P25024 | 2/20 | 0.64 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.64 |
| ▸ | RECQL | P46063 | 1/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.64 |
| ▸ | HPGD | P15428 | 1/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.64 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.64 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.64 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.64 |
| ▸ | THPO | P40225 | 1/20 | 0.64 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.64 |
| ▸ | CA12 | O43570 | 5/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1883564 | 1.00 | MAPT (0.64) | MAPTPTGS1PTGS2ALDH1A1SMN1; SMN2 | |
| SCHEMBL15486527 | 0.86 | MAPT (0.61) | MAPTPTGS1PTGS2ALDH1A1SMN1; SMN2 | |
| SCHEMBL7011096 | 0.85 | CA12 (0.61) | MAPTPTGS1PTGS2ALDH1A1SMN1; SMN2 | |
| SCHEMBL6277561 | 0.84 | MAPT (0.58) | MAPTPTGS1PTGS2ALDH1A1SMN1; SMN2 | |
| SCHEMBL6319806 | 0.84 | MAPT (0.58) | MAPTPTGS1PTGS2ALDH1A1SMN1; SMN2 | |
| SCHEMBL6282924 | 0.84 | MAPT (0.58) | MAPTPTGS1PTGS2ALDH1A1SMN1; SMN2 | |
| SCHEMBL13939943 | 0.83 | CXCR2 (0.64) | PTGS2ALDH1A1LMNACXCR1CXCR2 | |
| SCHEMBL7011092 | 0.82 | CA12 (0.57) | MAPTPTGS1PTGS2ALDH1A1SMN1; SMN2 | |
| SCHEMBL6286873 | 0.82 | HTT (0.63) | MAPTPTGS1PTGS2ALDH1A1SMN1; SMN2 | |
| SCHEMBL6315710 | 0.82 | CA12 (0.57) | MAPTPTGS1PTGS2ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7939521-B2 | 2-arylpropionic acid derivatives and pharmaceutical compositions containing them | DompePHA.R.MA S.p.A. (IT) | 2011-05-10 | — | — | US | disclosed |
| US-20080312293-A1 | 2-Arylpropionic Acid Derivatives and Pharmaceutical Compositions Containing Them | DOMPE' PHA.R.MA.S.P.A. (IT) | 2008-12-18 | — | — | US | disclosed |
| US-6887903-B1 | N-(2-aryl-propionyl)-sulfonamides and pharmaceutical preparations containing them | DOMPE S.P.A. (IT) | 2005-05-03 | — | — | US | disclosed |
| US-6881755-B2 | N-(2-aryl-propionyl)-sulfonamides and pharmaceutical preparations containing them | Dompé S.p.A. (IT) | 2005-04-19 | — | — | US | disclosed |
| US-20030216392-A1 | N - ( 2 - aryl - propionyl ) - sulfonamides and pharmaceutical preparations containing them | DOMPE S.P.A. | 2003-11-20 | — | — | US | disclosed |
| EP-1123276-B1 | N-(2-ARYL-PROPIONYL)-SULFONAMIDES AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM | DOMPE SPA (IT) | 2003-01-08 | — | — | EP | disclosed |
| EP-1123276-A1 | N-(2-ARYL-PROPIONYL)-SULFONAMIDES AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM | Dompe' S.P.A. (IT) | 2001-08-16 | — | — | EP | disclosed |
| WO-2000024710-A1 | N-(2-ARYL-PROPIONYL)-SULFONAMIDES AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM | DOMPE' S.P.A. (IT) | 2000-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216392-A1 | N - ( 2 - aryl - propionyl ) - sulfonamides and pharmaceutical preparations containing them | ELANE, MPO, FPR1 | MAPT 4727/4885PTGS1 29/4885PTGS2 48/4885 |
| US-20080312293-A1 | 2-Arylpropionic Acid Derivatives and Pharmaceutical Compositions Containing Them | C3AR1, C5AR2, C5AR1 | MAPT 4400/4885PTGS1 197/4885PTGS2 137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.